博拓生物
(688767)
| 流通市值：38.20亿 | | | 总市值：38.20亿 |
| 流通股本：1.07亿 | | | 总股本：1.07亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 388,778,942.37 | 267,157,032.6 | 135,626,648.51 | 442,110,404.25 |
| 营业收入 | 388,778,942.37 | 267,157,032.6 | 135,626,648.51 | 442,110,404.25 |
| 二、营业总成本 | 287,401,539.14 | 181,869,640.78 | 91,142,982.46 | 298,968,264.87 |
| 营业成本 | 200,978,577.1 | 137,183,162.86 | 74,822,867.8 | 219,590,245.23 |
| 税金及附加 | 6,246,606.72 | 4,805,936.15 | 1,348,082.07 | 5,455,337.33 |
| 销售费用 | 18,163,369.19 | 11,334,817.85 | 4,488,401.71 | 27,882,758.92 |
| 管理费用 | 47,781,511.35 | 32,038,152.2 | 13,005,826.89 | 51,325,909.73 |
| 研发费用 | 43,944,660.52 | 30,359,777.53 | 14,645,403.84 | 80,475,253.93 |
| 财务费用 | -29,713,185.74 | -33,852,205.81 | -17,167,599.85 | -85,761,240.27 |
| 其中:利息费用 | 27,297.03 | 22,919.99 | - | 136,617.26 |
| 其中:利息收入 | 39,364,190.82 | 30,648,560.26 | - | 73,525,036.35 |
| 加:公允价值变动收益 | - | - | - | 0 |
| 加:投资收益 | 4,967,633.59 | 1,022,177.34 | -271,329.44 | 3,379,945.24 |
| 资产处置收益 | -49,756.6 | -49,756.6 | -49,756.6 | 2,262.49 |
| 资产减值损失(新) | -9,368,841.1 | -5,568,017.27 | -405,996.24 | -55,274,643.2 |
| 信用减值损失(新) | -1,376,065.23 | -500,354.38 | 236,675.18 | -3,561,762.73 |
| 其他收益 | 3,821,710.24 | 887,289.66 | 541,941.93 | 29,135,732.03 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 99,372,084.13 | 81,078,730.57 | 44,535,200.88 | 116,823,673.21 |
| 加:营业外收入 | 109,490.7 | 110,416.94 | 2,691.48 | 608,146.95 |
| 减:营业外支出 | 7,350.53 | 4,615.61 | 1,254.41 | 1,554,722.69 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 99,474,224.3 | 81,184,531.9 | 44,536,637.95 | 115,877,097.47 |
| 减:所得税费用 | 12,835,035.44 | 10,748,415.61 | 5,002,305.82 | 10,577,296.76 |
| 六、净利润 | 86,639,188.86 | 70,436,116.29 | 39,534,332.13 | 105,299,800.71 |
| 持续经营净利润 | 86,639,188.86 | 70,436,116.29 | 39,534,332.13 | 105,299,800.71 |
| 归属于母公司股东的净利润 | 89,211,721.37 | 72,175,097.19 | 39,631,348.59 | 106,605,811.85 |
| 少数股东损益 | -2,572,532.51 | -1,738,980.9 | -97,016.46 | -1,306,011.14 |
| (一)基本每股收益 | 0.85 | 0.69 | 0.38 | 1 |
| (二)稀释每股收益 | 0.85 | 0.69 | 0.38 | 1 |
| 八、其他综合收益 | -1,791,331.89 | 933,324.22 | 256,146.39 | -1,569,443.72 |
| 归属于母公司股东的其他综合收益 | -1,845,569.84 | 922,625.87 | 250,178.88 | -1,564,632.29 |
| 九、综合收益总额 | 84,847,856.97 | 71,369,440.51 | 39,790,478.52 | 103,730,356.99 |
| 归属于母公司股东的综合收益总额 | 87,366,151.53 | 73,097,723.06 | 39,881,527.47 | 105,041,179.56 |
| 归属于少数股东的综合收益总额 | -2,518,294.56 | -1,728,282.55 | -91,048.95 | -1,310,822.57 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |